The Food and Drug Administration approved Novo Nordisk’s Ozempic as the first GLP-1 treatment option for people with type 2 ...

GLP-1 medications are renowned for their ability to treat type 2 diabetes and aid weight loss. Now, there's a new benefit to ...

Ozempic’s expanded approval in the U.S. could transform how doctors treat patients with the condition, which involves a ...

Regulators have approved the drug as a treatment for weight loss, Type 2 diabetes and lowering the risk of heart attacks and ...

“The impact on not just kidney disease but also cardiovascular disease and on all-cause death.” Ozempic and other semaglutide ...

Ozempic, or semaglutide, can now be used to reduce the risk of worsening kidney disease or kidney failure in adults with type ...

The U.S. FDA has approved Novo Nordisk's Ozempic for reducing the risk of kidney failure and disease progression, as well as ...

in adults with type 2 diabetes and chronic kidney disease. Ozempic is already widely used and was first FDA-approved in 2017 to treat type 2 diabetes. The medication — taken weekly by injection ...

Chronic kidney disease affects about 37 million adults in the United States and is expected to rise. It is a common ...

When Novo Nordisk unveiled kidney outcomes data for its star GLP-1 medicine Ozempic last May, the company’s executive medical ...